Evidence map›Paper›PMID 36290365›Full record

ArticleBiology2022

Application of Multigene Panels Testing for Hereditary Cancer Syndromes.

Airat Bilyalov, Sergey Nikolaev, Leila Shigapova, Igor Khatkov, Anastasia Danishevich, Ludmila Zhukova, Sergei Smolin, Marina Titova, Tatyana Lisica, Natalia Bodunova and 2 more

Open access · goldAbstract read
In one paragraph

Article in Biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Biomedicines · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Airat BilyalovInstitute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia.ORCID 0000-0002-8888-8395
Sergey NikolaevThe Loginov Moscow Clinical Scientific Center, 111123 Moscow, Russia.
Leila ShigapovaInstitute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia.
Igor KhatkovThe Loginov Moscow Clinical Scientific Center, 111123 Moscow, Russia.
Anastasia DanishevichThe Loginov Moscow Clinical Scientific Center, 111123 Moscow, Russia.
Ludmila ZhukovaThe Loginov Moscow Clinical Scientific Center, 111123 Moscow, Russia.
Sergei SmolinThe Loginov Moscow Clinical Scientific Center, 111123 Moscow, Russia.
Marina TitovaInstitute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia.
Tatyana LisicaCentre for Strategic Planning of FMBA of Russia, 119121 Moscow, Russia.
Natalia BodunovaThe Loginov Moscow Clinical Scientific Center, 111123 Moscow, Russia.
Elena ShagimardanovaInstitute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia.ORCID 0000-0003-2339-261X
Oleg GusevInstitute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia.
Moscow Clinical Scientific Center · RUKazan Federal University · RUCenter for Strategic Research · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundApproximately 5-10% of all cancers are associated with hereditary cancer predisposition syndromes (HCPS). Early identification of HCPS is facilitated by widespread use of next-generation sequencing (NGS) and brings significant benefits to both the patient and their relatives. This study aims to evaluate the landscape of genetic variants in patients with personal and/or family history of cancer using NGS-based multigene panel testing. MATERIALS AND

methodsThe study cohort included 1117 probands from Russia: 1060 (94.9%) patients with clinical signs of HCPS and 57 (5.1%) healthy individuals with family history of cancer. NGS analysis of 76 HCPS genes was performed using a custom Roche NimbleGen enrichment panel.

resultsPathogenic/likely pathogenic variants were identified in 378 of 1117 individuals (33.8%). The predominant number (59.8%) of genetic variants was identified in

conclusionsMultigene panel testing allows for a differential diagnosis and identification of high-risk group for oncological diseases. Our results demonstrate that inclusion of non-coding gene regions into HCPS gene panels is highly important for the identification of rare spliceogenic variants with high penetrance.

Indexed as

hereditary cancermultigene panelsNGS

Identifiers

PMID36290365
PMCPMC9598138
OpenAlexW4303614001

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.